{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:57Z","timestamp":1787020317838,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bio Farma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Typhoid fever caused by Salmonella enteric serovar Typhi (\n                      <jats:italic>S. Typhi<\/jats:italic>\n                      ) is a common cause of morbidity in the world. In 2017, 14.3 million cases of Typhoid and paratyphoid fever occurred globally. School age children between 3 to 19\u2009years old are the most affected. Poor sanitation and multi drug resistance have increased the need for vaccines to reduce the global burden of disease. Based on previous trials, typhoid conjugate vaccines have longer- lasting protection, higher efficacy, require fewer doses and are suitable from infancy that allows them to be incorporated into the routine immunization program. Our previous phase I trial proved that a novel Vi-DT typhoid conjugate vaccine is safe and immunogenic in subjects 2\u20135 and 18\u201340\u2009years. Our phase II trial consisted of subjects 6\u2009months to 40\u2009years. Our previously published paper on subjects 6 to &lt;\u200924\u2009months proved that this vaccine is safe and immunogenic for this age group. Therefore, with this paper we aimed to evaluate the safety and immunogenicity in children 2\u201311\u2009years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized, observer-blind, superiority design of Vi-DT Typhoid conjugate vaccine compared to Vi-polysaccharide vaccine (Vi-PS) phase II study was conducted from October 2018 to December 2018 where 200 subjects aged 2\u201311\u2009years were recruited. A blood sample prior to vaccination was taken, followed by administration of a single dose of either test vaccine (Vi-DT) or control vaccine (Vi-PS) and then a second blood sample was collected 28\u2009days post vaccination. Adverse reactions were assessed and antibody increment was evaluated at 28\u2009days post vaccination through collected serum sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pain was the most common local reaction. Fever and muscle pain were the most common systemic reactions. Both Vi-DT and Vi-PS groups had roughly the same number of adverse reactions. At 28\u2009days post vaccination, 100% of subjects in the Vi-DT group and 93% of subjects in the Vi-PS group produced antibody increment \u22654 times. The Vi-DT group produced a higher GMT as compared to Vi-PS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vi-DT vaccine is safe and immunogenic in children 2\u201311\u2009years old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Trial registration number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03460405\">NCT03460405<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-020-02375-4","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T03:02:59Z","timestamp":1602730979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2\u201311\u2009years: a phase II preliminary report"],"prefix":"10.1186","volume":"20","author":[{"given":"Bernie Endyarni","family":"Medise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soedjatmiko","family":"Soedjatmiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartono","family":"Gunardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini","family":"Sekartini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hindra Irawan","family":"Satari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Rezeki","family":"Hadinegoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angga","family":"Wirahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita","family":"Puspita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini Mulia","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Sil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novilia Sjafri","family":"Bachtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2375_CR1","doi-asserted-by":"publisher","first-page":"020407","DOI":"10.7189\/jogh.05.020407","volume":"5","author":"A Azmatullah","year":"2015","unstructured":"Azmatullah A, Qamar FN, Thaver D, Zaidi AK, Bhutta ZA. Systematic review of the global epidemiology, clinical and laboratory profile of enteric fever. J Glob Health. 2015;5:020407.","journal-title":"J Glob Health"},{"key":"2375_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/649541","volume":"50","author":"JA Crump","year":"2010","unstructured":"Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:241\u20136. Medline: 20014951. https:\/\/doi.org\/10.1086\/649541.","journal-title":"Clin Infect Dis"},{"key":"2375_CR3","first-page":"346","volume":"82","author":"JA Crump","year":"2004","unstructured":"Crump JA, Luby SP, Ed M. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346\u201353 Medline:15298225..","journal-title":"Bull World Health Organ"},{"key":"2375_CR4","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","volume":"2","author":"V Mogasale","year":"2014","unstructured":"Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2:e570\u201380.","journal-title":"Lancet Glob Health"},{"issue":"Suppl 3","key":"2375_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4269\/ajtmh.18-0032","volume":"99","author":"A Radhakrishnan","year":"2018","unstructured":"Radhakrishnan A, Als D, Mintz ED, Cump JA, Stanaway J, Breiman RF, et al. Introductory article on global burden and epidemiology of typhoid fever. Am J Trop Med Hyg. 2018;99(Suppl 3):4\u20139. https:\/\/doi.org\/10.4269\/ajtmh.18-0032.","journal-title":"Am J Trop Med Hyg"},{"key":"2375_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","volume":"19","author":"GBD","year":"2019","unstructured":"GBD. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the global burden of disease study 2017. Lancet Infect Dis. 2019;19:369\u201381. https:\/\/doi.org\/10.1016\/S1473-3099(18)30685-6.","journal-title":"Lancet Infect Dis"},{"key":"2375_CR7","unstructured":"Background paper to SAGE on Typhoid Vaccine Policy Recommendation. Prepared by the SAGE Working Group on Typhoid Vaccines and the WHO Secretariat. 24 September 2017."},{"issue":"11","key":"2375_CR8","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/cix229","volume":"64","author":"C Britto","year":"2017","unstructured":"Britto C, Pollard AJ, Voysey M, Blohmke CJ. An appraisal of the clinical features of pediatric enteric fever: systematic review and meta-analysis of the age- stratified disease occurrence. Clin Infect Dis. 2017;64(11):1604\u201311. https:\/\/doi.org\/10.1093\/cid\/cix229.","journal-title":"Clin Infect Dis"},{"key":"2375_CR9","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3201\/eid1609.100125","volume":"16","author":"NA Feasey","year":"2010","unstructured":"Feasey NA, Archer BN, Heyderman RS, et al. Typhoid fever and invasive nontyphoid salmonellosis, Malawi and South Africa. Emerg Infect Dis. 2010;16:1448\u201351.","journal-title":"Emerg Infect Dis"},{"key":"2375_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2471\/BLT.06.039818","volume":"86","author":"RL Ochiai","year":"2008","unstructured":"Ochiai RL, Acosta CJ, Danovaro-Holiday MC, Balqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86:260\u20138. PMID: 18438514. https:\/\/doi.org\/10.2471\/BLT.06.039818.","journal-title":"Bull World Health Organ"},{"key":"2375_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJMp1803926","volume":"379","author":"JR Andrews","year":"2018","unstructured":"Andrews JR, Qamar FN, Charles RC, Ryan ET. Extensively drug-resistant typhoid \u2014 are conjugate vaccines arriving just in time? N Engl J Med. 2018;379:1493\u20135. https:\/\/doi.org\/10.1056\/NEJMp1803926.","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"2375_CR12","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1093\/cid\/ciy1124","volume":"68","author":"S Saha","year":"2019","unstructured":"Saha S, Islam M, Sajib M, Saha SH, Jamaluddin M, Hooda Y, et al. Epidemiology of Typhoid and Paratyphoid: Implications for Vaccine Policy. Clin Infect Dis. 2019;68(Supplement_2):S117\u201323. https:\/\/doi.org\/10.1093\/cid\/ciy1124.","journal-title":"Clin Infect Dis"},{"key":"2375_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/QCO.0000000000000479","volume":"31","author":"MM Gibani","year":"2018","unstructured":"Gibani MM, Britto C, Pollard AJ. Typhoid and paratyphoid fever: a call to action. Curr Opin Infect Dis. 2018;31:440\u20138. https:\/\/doi.org\/10.1097\/QCO.0000000000000479.","journal-title":"Curr Opin Infect Dis"},{"key":"2375_CR14","doi-asserted-by":"publisher","unstructured":"Sahastrabuddhe S, Saluja T. Overview of the typhoid conjugate vaccine pipeline: current status and future plans. Infect Dis Soc Am. 2019. https:\/\/doi.org\/10.1093\/cid\/ciy884.","DOI":"10.1093\/cid\/ciy884"},{"key":"2375_CR15","doi-asserted-by":"publisher","unstructured":"Antill\u00f3n M, Bilcke J, Paltiel D, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017. https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.001.","DOI":"10.1016\/j.vaccine.2017.05.001"},{"key":"2375_CR16","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","volume":"390","author":"C Jin","year":"2017","unstructured":"Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472\u201380.","journal-title":"Lancet"},{"issue":"3","key":"2375_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/civ295","volume":"61","author":"VK Mohan","year":"2015","unstructured":"Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Safety and Immunogenicity of a Vi Polysaccharide\u2013Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. Clin Infect Dis. 2015;61(3):393\u2013402. https:\/\/doi.org\/10.1093\/cid\/civ295.","journal-title":"Clin Infect Dis"},{"key":"2375_CR18","doi-asserted-by":"crossref","unstructured":"Pitzer VE, Bowles CC, Baker S, Kang G, Balaji V, Farrar J, Grenfell B. Predicting the Impact of Vaccination on the Transmission Dynamics of Typhoid in South Asia: A Mathematical Modeling Study. PLoS One. 2014;8(1):1.","DOI":"10.1371\/journal.pntd.0002642"},{"key":"2375_CR19","first-page":"153","volume-title":"WHO Position Paper on Typhoid vaccines","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO Position Paper on Typhoid vaccines, vol. 93; 2018. p. 153\u201372."},{"key":"2375_CR20","doi-asserted-by":"publisher","unstructured":"Neuzil KM, Pollard AJ, Marfin AA. Introduction of typhoid conjugate vaccines in Africa and Asia. Infect Dis Soc erica. 2019. https:\/\/doi.org\/10.1093\/cid\/ciy878.","DOI":"10.1093\/cid\/ciy878"},{"key":"2375_CR21","doi-asserted-by":"publisher","first-page":"8,673","DOI":"10.1080\/14760584.2018.1496825","volume":"17","author":"JE Meiring","year":"2018","unstructured":"Meiring JE, Patel P, Patel P, Gordon MA. Typhoid conjugate vaccines: making vaccine history in Africa. Expert Rev Vaccines. 2018;17:8,673\u20136. https:\/\/doi.org\/10.1080\/14760584.2018.1496825.","journal-title":"Expert Rev Vaccines"},{"key":"2375_CR22","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","volume":"36","author":"MR Capeding","year":"2018","unstructured":"Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, et al. Safety and immunogenicity of a vi-DT typhoid conjugate vaccine: phase I trial in healthy Filipino adults and children. Vaccine. 2018;36:3794\u2013801.","journal-title":"Vaccine."},{"key":"2375_CR23","doi-asserted-by":"publisher","unstructured":"Capeding MR, Alberto E, Sil A, Saluja T, Teshome S, Ryun Kim D, et al. Immunogenicity, safety and reactogenicity of a phase II trial of vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.074.","DOI":"10.1016\/j.vaccine.2019.09.074"},{"issue":"2","key":"2375_CR24","doi-asserted-by":"publisher","first-page":"e0211784","DOI":"10.1371\/journal.pone.0211784","volume":"14","author":"BE Medise","year":"2019","unstructured":"Medise BE, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S, et al. Six-month follow up of a randomized clinical trial phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS One. 2019;14(2):e0211784. https:\/\/doi.org\/10.1371\/journal.pone.0211784.","journal-title":"PLoS One"},{"key":"2375_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2020.01.045","volume":"93","author":"BE Medise","year":"2020","unstructured":"Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, et al. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: safety and immunogenicity of vi-DT typhoid conjugate vaccine. Int J Infect Dis. 2020;93:102\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.045.","journal-title":"Int J Infect Dis"},{"key":"2375_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biologicals.2018.09.001","volume":"56","author":"S Rijpkemaa","year":"2018","unstructured":"Rijpkemaa S, Hockley J, Logana A, Rigsby P, Atkinson E, Jin C, et al. Establishment of the first international standard for human anti-typhoid capsular vi polysaccharide IgG. Biologicals. 2018;56:29\u201338.","journal-title":"Biologicals."},{"key":"2375_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","volume":"12","author":"M Mitra","year":"2016","unstructured":"Mitra M, Shah N, Ghosh A, et al. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: school-based cluster randomized study. Hum Vaccin Immunother. 2016;12:939\u201345.","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-020-02375-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T10:56:40Z","timestamp":1634295400000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-020-02375-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1186\/s12887-020-02375-4","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Trial registration was done and approved by\n                      \n                      . Clinical trial registration number: NCT03460405. Registered 9th March 2018. URL:\n                      \n                      This trial was also registered and approved by the Ethics Committee of Universitas Indonesia <i>with reference number<\/i> 0276\/UN2.F1\/ETIK\/2018 <i>as well as<\/i> Indonesian Trial registry with registry number INA-35ST1PS.All parents of subjects were given an explanation of the trial as well as their rights and responsibilities as subjects, after which they signed an informed consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by PT Bio Farma, Indonesia. Data analysis and interpretation was solely done by investigators and the funding body was not involved in this process. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}